GlassScriptPhysician profile
Michael K Mcevoy
NPI 1669558219
$9,727.60
in general payments reported to CMS, 2019-2025
50 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $1,170 · 2021: $1,893 · 2022: $1,735 · 2023: $1,462 · 2024: $1,310 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,909.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,258.64 | 2020-2025 | |
| Novo Nordisk INC | $941.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $937.27 | 2019-2025 | |
| Amgen INC. | $778.08 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $676.66 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amarin Pharma, INC. | $553.06 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $543.75 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $534.81 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.88 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $324.62 | 2019-2024 | Veozah |
| Esperion Therapeutics, INC. | $293.49 | 2021-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $267.66 | 2019-2023 | Trintellix |
| Eisai INC. | $215.42 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $209.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $165.28 | 2019-2024 | Xarelto |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $161.81 | 2019-2020 | |
| Antares Pharma, INC. | $125.82 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $120.05 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.37 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $92.36 | 2021-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Lundbeck LLC | $83.07 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $75.02 | 2023-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $72.16 | 2021-2025 | |
| Exact Sciences Corporation | $66.85 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Seqirus USA INC | $64.40 | 2020-2025 | Fluad, Flucelvax |
| Biohaven Pharmaceuticals, INC. | $62.69 | 2021 | |
| Sumitomo Pharma America, INC. | $56.55 | 2023-2025 | Gemtesa |
| Mdd US Operations, LLC | $50.71 | 2019-2020 | |
| Horizon Therapeutics Plc | $49.94 | 2019-2022 | |
| Bausch Health US, LLC | $40.62 | 2019-2022 | |
| Abbott Laboratories | $39.31 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $37.05 | 2022 | |
| Medtronic, INC. | $33.79 | 2021-2022 | |
| Halozyme INC | $33.63 | 2023 | |
| Mylan Specialty L.P. | $32.78 | 2019-2020 | |
| Nevro Corp. | $31.97 | 2022-2023 | Senza |
| Acerus Pharmaceuticals Corporation | $28.31 | 2021-2022 | |
| Neurelis, INC. | $27.18 | 2023 | Valtoco |
| Hikma Pharmaceuticals USA | $24.23 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $21.32 | 2024 | Kristalose |
| Dexcom, INC. | $21.29 | 2025 | Dexcom G6 Transmitter |
| Insightec,INC | $20.62 | 2025 | Exablate |
| Watermark Medical, INC. | $19.77 | 2024 | |
| Jazz Pharmaceuticals INC. | $17.31 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.78 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.21 | 2023 | Xyosted, Qelbree, Tlando |
| Genentech USA, INC. | $13.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.91 | 2020 | |
| Neos Therapeutics, LP | $12.86 | 2019 | |
| Aytu Biopharma, INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcevoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.